Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy

Sergey G Klochkov; Margarita E Neganova; Nagendra Sastry Yarla; Madhukiran Parvathaneni; Bechan Sharma; Vadim V Tarasov; George Barreto; Sergey O Bachurin; Ghulam Md Ashraf; Gjumrakch Aliev

doi:10.1016/j.semcancer.2017.10.010

Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy

Semin Cancer Biol. 2019 Jun:56:128-134. doi: 10.1016/j.semcancer.2017.10.010. Epub 2017 Oct 31.

Affiliations

¹ Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russia.
² Divisions of Biochemistry & Chemistry City University of New York School of Medicine, 160 Convent Avenue, New York, NY 10031, USA.
³ Department of Biotechnology, Harrisburg University of Science & Technology, 326 Market Street, Harrisburg, PA 17101, USA.
⁴ Department of Biochemistry, University of Allahabad, Allahabad, U.P., India.
⁵ Sechenov First Moscow State Medical University, 119991, Moscow, Russia.
⁶ Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia.
⁷ King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
⁸ Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russia; School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, USA; GALLY International Biomedical Research Institute Inc., 7733 Louis Pasteur Drive, #330, San Antonio, TX, 78229, USA. Electronic address: aliev03@gmail.com.

PMID: 29100957
DOI: 10.1016/j.semcancer.2017.10.010

Abstract

Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.

Keywords: Cancer; Farnesyltransferase; Farnesyltransferase inhibitor; Ras protein; Therapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Clinical Trials as Topic
Enzyme Inhibitors / pharmacology*
Enzyme Inhibitors / therapeutic use
Farnesyltranstransferase / antagonists & inhibitors*
Farnesyltranstransferase / metabolism*
Gene Expression Regulation, Neoplastic
Genes, ras
Humans
Molecular Targeted Therapy
Neoplasms / drug therapy
Neoplasms / etiology
Neoplasms / metabolism*
Neoplasms / pathology
Protein Binding
Signal Transduction
Treatment Outcome

Substances

Antineoplastic Agents
Enzyme Inhibitors
Farnesyltranstransferase